Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population.

ABSTRACT:

Background

Lung cancer screening trials generally enroll motivated, relatively healthy, and adherent populations. We therefore evaluated the prevalence and effects of comorbidities in a real-world population undergoing low-dose computed tomography (LDCT) scans.

Patients and methods

We calculated the Charlson Comorbidity Index (CCI) of patients for whom an initial low-dose computed tomography (LDCT) for lung cancer screening was ordered between February 2017 and February 2019 in an integrated safety-net healthcare system. We examined the association between CCI and initial LDCT completion using multivariable logistic regression, assessed the association between specific medical comorbidity and LDCT completion using Chi-square test or Fisher's exact test as appropriate, and ex

SUBMITTER: Majeed H 

PROVIDER: S-EPMC9287827 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature